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Imatinib has become the standard primary approach for the
treatment of a newly diagnosed chronic phase myeloid leukemia
(CML) patient, recently. Complete cytogenetic response is
achieved on the majority of patients under treatment, but the
disease remains in molecular level and after discontinuation of the
drug, relapses occur inevitably. In imatinib era centers are referring
only the patients, who has imatinib resistance or patients with high
relapse risk. Secondly, the period from diagnosis to transplantation
is an important nominator. In imatinib era CML patients will ﬁrst
undergo a trial of imatinib and according to the response they will
be referred to the allogeneic transplant program. There is lack of
data about the impact of delayed referral and emerging imatinib
resistance on allogeneic transplant outcome. We have performed a
case-matched control analysis in our CML (n: 173). CML patients
who received imatinib before transplantation (n20), were
matched according EBMT (Gratwohl) score with imatinib naive
ones (n40). The median age at transplant in the imatinib group
was 39 (19-57), gender F/M: 10/10, disease status 1st CP:13, 2nd
CP: 4, AP: 2, BP: 1. The median total imatinib dose that was used
until transplantation was 93gr (33-648), and imatinib therapy was
discontinued at a median of 17, 5 (7-210) days prior to the trans-
plantation. Only one of 20 patients was in molecular remission
before transplantation. according to the EBMT score. The median
age of 40 patients in imatinib naı¨ve group was 34 years (14-53),
gender F/M: 14/26, and disease status 1st CP:32, 2nd CP:2, AP: 3,
BP: 3. The two groups were similar according to their age, sex,
conditioning regimen, stem cell sources and Grathwohl scores.
Engraftment for neutrophil 0,5109/L, and platelet 
20109/L was median 15 (13-20) days and 13 (10-32) days in the
imatinib group while it is 16 (0-28) days and 15 (0-36) days in the
imatinib naive group. The response to transplantation, transplan-
tation related mortality, the incidence of acute and chronic
GVHDH for each group were not signiﬁcantly different. More-
over, no signiﬁcant difference was determined between 2-year’s
disease free survival and overall survival rates (Table). Our single
center analysis is in concordance with several recent reports. In this
study, it is observed that imatinib use prior to AHSCT does not
negatively affect the early transplant related outcome.
STI () n: 20 STI (-) n: 40 p
Median age 39 (18-57) 34 (14-53) 0,160
Grathwohl score
(1,2,3,4) 1/2/7/6/4 1/6/20/10/3 0,545
Time Diagnosis-
Transplant (month) 16,9 (5,4-75,8) 11,6 (4,2-129,3) 0,076
Stem cell source (PB/
BM) 15/5 30/10
Conditioning regimen
(Ablative/RIC) 10/10 28/12 0,161
Sex (Female/Male) 10/10 14/26 0,751
Engraftment 19/20 39/40 0,559
NEU>0.510e9/L 15 (13-20) 16 (0-28) 0,639
Transplantation-
related mortality 3/20 6/40 1
Acute GvHD (II-IV) 3/19 17/40 0,076
Chronic GvHD 8/16 22/34 0,322
Relapse rate 3/20 14/40 0,136
2-year’s disease free
survival % 55,4%13,2 % 46,7%7,9 0,595
2-year’s overall
survival %71,513,4 % 59,4%7,9 0,463
PB: Peripheral blood, BM: Bone morrow, RIC: Reduced intensity
conditioning
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HUMAN HERPESVIRUS-6 ENCEPHALITIS FOLLOWING ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
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Approximately 50% recipients of allo-HSCT develop human
herpes virus-6 (HHV-6) viremia detectable by polymerase chain
reaction ampliﬁcation (HHV-6 PCR), but the clinical signiﬁcance
of this asymptomatic viremia is unclear. Five of 53(9.4%) patients
who received Alemtuzumab (total dose, 40 mg) supported condi-
tioning (CY-TBI 3, BU-TBI1, Flu-Mel1, MUD 3,
MMUD 1, MMRD1) and Tacrolimus as GVHD prophylaxis
subsequently developed HHV-6 encephalitis whilst receiving an-
tiviral prophylaxis (Valciclovir 4 and Valganciclovir 1). Acute
GVHD (grade II 1, grade III2, grade IV2) preceded enceph-
alitis and had necessitated, prednisone 5, Inﬂiximab 1, Alemtu-
zumab 1, and Daclizumab 1. HSV-6 encephalitis became ap-
parrent at 41-103 days (median 60 days) presenting with confusion
(n5), amnesia (n 3) and seizures (n2). MRI revealed non-
speciﬁc white matter changes in 4 and a non enhancing medial
temporal lobe lesion in one of the patients. CSF protein was
elevated in 4 patients (table-1); CSF-pleocytosis was mild with a
median of 3- lymphocytes/hpf. HSV-6 PCR on blood (plasma)
revealed 100-22,500 (median 1200) DNA copies/ml. CSF PCR
was positive in all 5 patients at 600-225,000 (median 4700) copies/
ml). CSF HHV6 was several fold higher than plasma levels (table-
1). EEG was nonspeciﬁc in all 5 patients. Intravenous administra-
tion of foscarnet resulted in neurological improvement at 8-13
(median 11) days and negative plasma PCR at 30-66 (median 50)
days; recovery of short-term memory loss was more prolonged. In
the patient with negative plasma PCR, CSF PCR became negative
on 50th day of therapy. Four patients had complete neurological
recovery; one patient (#2) had transient improvement before suc-
cumbing to multi-organ failure. We conclude that, HSV-6 en-
cephalitis complicates approximately 10% of in vivo T cell depleted
allo-HSCT. Poor yield of routine CSF, MRI and EEG examina-
tion calls for high index of suspicion and CSF examination for
HHV-6 PCR. Prompt antiviral treatment with foscarnet appears
effective.
Table-1: HSV-6 Encephalitis following allo-HSCT
Age/
Sex
Onset/
Day Manifestation
HSV-6
CSF
(copy/ml)
HSV-6
Blood
(copy/ml) Outcome
Other
viral
infections
Follow-up
Months
46F 41 Amnesia,
confusion,
seizure
4700 Negative Complete
resolution
Herpes
zoster
Alive 12
months
66F 103 Confusion,
somnolence,
disorganized
speech
225,000 22,500 Transient
improvement
CMV Died day
147
41M 60 Amnesia,
confusion
Positive* 200 Complete
resolution
None Alive 36
months
39M 35 Amnesia,
confusion,
tremor
4800 100 Complete BK virus
resolution
Alive 6
months
58F 83 Seizure,
confusion
600 2700 Complete
resolution
None Died day
120
Abbreviations: M- male, F- female, allo-HSCT- allogeneic hema-
topoietic stem cell transplant, MRI- Magnetic resonance im-
aging, HHV- Human herpes virus, Prot- Protein, Leu- Leu-
kocytes, CSF- Cerebrospinal ﬂuid, WM- white mater, *
Quantitative PCR not available
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CD154:CD40 CO-STIMULATORY BLOCKADE AT PRIMARY BMT PRO-
MOTES ALLOGENEIC ENGRAFTMENT IN SECONDARY BMT BY BLOCK-
ING SENSITIZATION
Xu, H.1, Huang, Y.1, Hussain, L.-R.1, Yan, J.1, Ildstad, S.T.1 1Institute
for Cellular Therapeutics, University of Louisville, Louisville, KY.
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Introduction: The morbidity associated with ablative condition-
ing has prevented the widespread application of bone marrow (BM)
transplantation (BMT) to treat autoimmune diseases and hemo-
globinopathies. To reduce the risk-beneﬁt ratio of establishing
chimerism, less-toxic approaches for conditioning recipients have
been pursued. As one approaches the threshold for conditioning,
failure of durable chimerism occurs with an increasing frequency.
In the present studies, we evaluated the effect of non-ablative
conditioning regimens on sensitization after graft failure and BM
re-transplantation. Materials and Methods: Recipients were in-
fused with MHC-disparate BMC in the context of costimulatory
molecule blockade. In the primary BMT, B6 (H-2b) mice were
treated with anti-
-TCR mAb (day-3) and/or anti-CD154 (day0
and day3), but without any total body irradiation (TBI), then
transplanted with 15  106 allogeneic BALB/c (H-2d) BM cells.
Secondary BMT was performed 5-7 weeks after primary BMT
with 950 cGy TBI and 15  106 BALB/c BM cells. Results: As
expected, engraftment did not occur in mice after primary BMT.
All animals survived. After secondary BMT with 950 cGy TBI
conditioning, engraftment occurred in 25% of mice treated with
anti-
TCR alone at primary BMT. In contrast, all mice engrafted
after secondary BMT with initial treatment of anti-
TCR plus
anti-CD154, and 75% of mice engrafted with anti-CD154 treat-
ment alone at the ﬁrst BMT. Flow cytometry cross-match assay
was performed to detect anti-donor Abs in the sera collected 4
weeks after the ﬁrst BMT. The values are reported as mean
ﬂuorescence intensity (MFI). The Ab titers were 4.92.6 MFI in
mice treated with anti-CD154 and 4.00.4 in mice treated with
both anti-
TCR and anti-CD154 resembled the Ab level in naı¨ve
mice (3.40.5). Ab titers were signiﬁcantly higher in mice treated
with anti-
TCR mAb alone (47.771.3; P0.05) and the non-
mAb treated group (12334.7).Conclusion:These results suggest
that CD154:CD40 co-stimulatory blockade used at the time of
primary BMT promotes allogeneic engraftment in secondary
BMT after engraftment failure. The mechanism is that anti-
CD154 inhibits B cell activation and generation of alloantibody
after primary BMT. Circulating anti-donor Abs are therefore the
critical hurdle for the success of secondary BMT. These ﬁndings
could have a signiﬁcant impact on management of clinic recipients
who have failed at primary BMT and require retransplantation.
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THE IMPACT OF EARLY ONSET OF HEMOPHAGOCYTOSIS AFTER
TRANSPLANTATION ON THE OUTCOME OF ALLOGENIC STEM CELL
TRANSPLANTATION
Yasuda, T.1, Ito, M.1, Imahashi, N.1, Nisiwaki, S.1, Yanagisawa, M.1,
Takahashi, T.1, Kuwatuka, Y.1, Oba, T.1, Miyamura, K.1, Kodera, Y.1
1Nagoya First Red Cross Hospital, Nagoya, Aichi, Japan.
[Introduction] Recently, the concept of early onset of hemoph-
agocytosis after transplantation has been proposed, but the inci-
dence, pathological ﬁndings and prognosis have not clariﬁed. We
analyzed how the early onset of hemophagocytosis after transplan-
tation affects the outocome of allogenic stem cell transplantation.
[Patients and methods] Fifty-two patients received their trans-
plants at the Nagoya First Red Cross Hospital from May 2005 to
April 2006. Forty-ﬁve patients of the 52 patients received marrow
aspiration in early stage of transplantation (until day30), and were
included in the current study. Patients’ ages were from 17 to 65
(median 42) years old. Forty patients were malignant diseases, and
5 patients were non-malignant diseases. Nineteen patients received
reduced intensity stem cell transplantation (RIST) regimen, and 36
patients received conventional regimen. Thirty-two patients re-
ceived BMT, 8 patients received PBSCT, and 5 patients did CBT.
Clots of bone marrow were retrospectively analyzed by a pathol-
ogist, and they were divided into three groups according to the
intensity of pathological ﬁndings of hemophagocytosis as group A
(no hemophagocytosis), group B (mild hemophagocytosis) , and
group C (severe hemophagocytosis). We compare three groups
with the clinical parameters.
[Results] Twenty-two patients were included in group A (49%),
13 patients in group B (29%), and 10 patients in group C (22%).
The average of maximum T-bilirubin in early stage of transplan-
tation (until day 30) was 1.60 mg/dl (group A), 2.68 mg/dl (group
B), and 6.49 mg/dl (group C).There was signiﬁcant difference
between A group to C group (p0.01). Similarly, the average of
maximum creatinine was 0.78 mg/dl (group A), 0.75 mg/dl (group
B), and 1.26 mg/dl (group C). There was signiﬁcant difference
between A group and B group to C group (p0.01). Disease free
survival until day 100 was 4.5% (group A), 7.7% (group B) and
40% (group C) (p0.02).
[Conclusion] It is supposed that the occurrence of hemophago-
cytosis until day 30 were well associated with elevation of T-
bilirubin and creatinine, and early mortality. To conﬁrm a clinical
signiﬁcance of hemophagocytosis, farther studies are needed.
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ALTERATION OF NK TOLERANCE EARLY POST-ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION RESULTS IN NK ALLOREACTIVITY
DRIVEN BY LACK OF RECIPIENT HLA LIGAND FOR DONOR INHIBITORY
KIR
Yu, J.1, Chewning, J.1, Hsu, K.2 1Sloan-Kettering Institute, New York,
NY; 2Memorial Sloan-Kettering Cancer Center, New York, NY.
Donor NK alloreactivity can play a signiﬁcant role in hema-
topoietic cell transplantation (HCT) outcome by decreasing
leukemia relapse and increasing survival. How NK cells in HCT
behave through killer Ig-like receptor (KIR) recognition of
target cell HLA has been the subject of discussion, with evi-
dence supporting a “missing self HLA” mechanism, relevant to
KIR ligand incompatible (HLA-mismatched) HCT, and other
studies supporting a “missing HLA ligand” mechanism, relevant
to both HLA-matched and mismatched HCT. We propose that
in HCT these two mechanisms need not be mutually exclusive.
Using 6-color ﬂow cytometric analysis of intracellular IFN-
production, we evaluated the response of inhibitory KIR-ex-
pressing NK subsets following activation with 721.221, a target
cell line deﬁcient in class I expression, or with 721.221 trans-
fectants expressing the KIR ligands HLA-Cw3, -Cw4, or -Bw4.
NK cells from 10 KIR haplotype-A homozygous individuals and
from 7 T-cell depleted HCT donor-recipient pairs were evalu-
ated. In normal individuals, mature NK cells expressing inhib-
itory KIR speciﬁc for self-HLA were signiﬁcantly more respon-
sive to target cells lacking KIR ligand than NK cells expressing
inhibitory KIR for non-self HLA (P0.001), consistent with
“missing self” behavior. NK cells expressing KIR2DL3, 2DL1,
and 3DL1 all demonstrated similar response patterns, which
were predictable based on the HLA background of the individ-
ual. However, NK cells from HCT patients displayed signiﬁ-
cantly different response patterns to the same target cells: com-
pared to the NK subsets in the donor, the recipient NK
response to lack of HLA ligand, both self and non-self, was higher
at days 15-60 (P0.001), decreasing to donor levels by day 100.
Indeed, the response of NK cells speciﬁc for non-self HLA early
post-HCT was equivalent to the response of NK cells speciﬁc
for self-HLA in a normal individual. Thus, while the mature
NK cell achieves tolerance by preferentially endowing func-
tional competence to inhibitory KIR speciﬁc for self-HLA
(“missing self”), the stem cell-derived NK cell post-HCT
achieves this self-tolerance only after transitioning from a state
where all inhibitory KIR receptors are capable of recognizing
lack of ligand (“missing ligand”). These results indicate that NK
alloreactivity in HCT is driven by both mechanisms and that
HLA-identical HCT recipients beneﬁt from NK alloreactivity
early post-HCT due to lack of HLA ligand for donor inhibitory
KIR.
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HUMAN TREGS INDUCED BY ECDI-COUPLED APC FOR THE SUPPRES-
SION OF TRANSPLANTATION ALLORESPONSES
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